

GENENTA|SCIENCE

Gene Therapy for Tumors Treatment

The Italian Biotech Start-up founded by San Raffaele Hospital, Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner, raised a Euro 10 million (\$11 million) Series A round with the support of Banca Esperia.

Milan, March 5th, 2015. After a few weeks from the first closing, GENENTA SCIENCE banked an overall Euro 10.0 million (USD 11.0 million) Series A round, the company target.

- The funding campaign was supported by Banca Esperia, the Private Bank of Mediobanca (MB:IM) and Mediolanum (MED:IM).
- The private offering was oversubscribed.
- The Series A round was led by private investors: entrepreneurs, managers, HNWI, family offices.
- The entrance of new shareholders allows GENENETA SCIENCE to complete pre-clinical studies and to advance in the preparation of the clinical phase for its therapeutic protocols to treat tumors.

GENENTA SCIENCE

GENENTA SCIENCE develops a gene transfer strategy into autologous hematopoietic stem cells (HSCs) to target interferon- α expression to tumor-infiltrating monocytes/macrophages.

An HIV-derived and genetically disabled viral vector - Lentivirus - delivers the gene into the HSCs.

Interferon is a protein usually produced by the body in response to infections that also exhibits a powerful anti-tumor activity. However, the clinical use of interferon as a drug has been limited by its high toxicity.

Thanks to GENENTA SCIENCE's innovative therapy, using a combination of transcriptional and microRNA-mediated control, tumor-infiltrating monocytes/macrophages become capable to selectively express interferon limited to the tumor area, thus reducing its toxicity.

Based on these mechanisms, a population of tumor-infiltrating monocytes/macrophages, TIE2-expressing monocytes (TEMs) with proangiogenic activity, are "armed" with a specific drug.

San Raffaele Hospital - an European leader in private healthcare with 18 hospitals, Euro 1.4 billion of revenues, over 15.000 employees and 3.9 million patients, Pierluigi Paracchi - former investor and board member at Ethical Oncology Science, and the scientists, Luigi Naldini - Director of the San Raffaele-Telethon Institute for Gene Therapy, TIGET and of the Division of Regenerative Medicine, Stem Cells and Gene Therapy, San Raffaele Hospital; Professor of Histology and of Gene and Cell Therapy, San Raffaele University - and Bernhard Gentner - Haematologist and Physician Scientist at the San Raffaele Hospital and TIGET, are the founders of the company.

Pierluigi Paracchi, Chairman and CEO
+39 335.73.51.868
pierluigi.paracchi@GENENETA.com

GENENTA SCIENCE SRL
Via Olgettina, 60 - 20132 Milan (Italy)